Price T Rowe Associates Inc. MD Buys 1,220 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Price T Rowe Associates Inc. MD raised its holdings in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 20.1% in the fourth quarter, HoldingsChannel reports. The firm owned 7,288 shares of the specialty pharmaceutical company’s stock after buying an additional 1,220 shares during the quarter. Price T Rowe Associates Inc. MD’s holdings in ANI Pharmaceuticals were worth $403,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of ANIP. abrdn plc bought a new position in ANI Pharmaceuticals during the 4th quarter valued at approximately $13,155,000. Barclays PLC raised its position in ANI Pharmaceuticals by 1,681.2% during the 3rd quarter. Barclays PLC now owns 143,033 shares of the specialty pharmaceutical company’s stock valued at $8,534,000 after purchasing an additional 135,003 shares during the last quarter. Assenagon Asset Management S.A. raised its position in ANI Pharmaceuticals by 67.4% during the 4th quarter. Assenagon Asset Management S.A. now owns 311,617 shares of the specialty pharmaceutical company’s stock valued at $17,226,000 after purchasing an additional 125,438 shares during the last quarter. Global Alpha Capital Management Ltd. raised its position in shares of ANI Pharmaceuticals by 16.4% in the 4th quarter. Global Alpha Capital Management Ltd. now owns 624,550 shares of the specialty pharmaceutical company’s stock worth $34,525,000 after acquiring an additional 88,100 shares in the last quarter. Finally, Walleye Capital LLC bought a new position in shares of ANI Pharmaceuticals in the 4th quarter worth approximately $3,981,000. Institutional investors own 76.05% of the company’s stock.

ANI Pharmaceuticals Stock Performance

Shares of ANIP stock opened at $60.37 on Thursday. The business’s fifty day simple moving average is $66.92 and its 200-day simple moving average is $60.73. The company has a market cap of $1.31 billion, a PE ratio of -109.76 and a beta of 0.56. The company has a current ratio of 2.74, a quick ratio of 1.97 and a debt-to-equity ratio of 1.52. ANI Pharmaceuticals, Inc. has a 12-month low of $52.50 and a 12-month high of $77.00.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its earnings results on Friday, May 9th. The specialty pharmaceutical company reported $1.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.37 by $0.33. ANI Pharmaceuticals had a positive return on equity of 15.87% and a negative net margin of 1.28%. The firm had revenue of $197.12 million for the quarter, compared to the consensus estimate of $179.75 million. During the same period in the prior year, the firm earned $0.82 EPS. The firm’s revenue was up 43.4% on a year-over-year basis. Analysts expect that ANI Pharmaceuticals, Inc. will post 3.86 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other ANI Pharmaceuticals news, SVP Krista Davis sold 1,000 shares of the stock in a transaction dated Friday, March 7th. The stock was sold at an average price of $60.86, for a total transaction of $60,860.00. Following the sale, the senior vice president now directly owns 66,525 shares of the company’s stock, valued at approximately $4,048,711.50. This trade represents a 1.48% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, VP Meredith Cook sold 400 shares of the stock in a transaction dated Monday, April 14th. The stock was sold at an average price of $68.96, for a total value of $27,584.00. Following the sale, the vice president now directly owns 80,145 shares in the company, valued at $5,526,799.20. This represents a 0.50% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 2,800 shares of company stock valued at $173,976. Company insiders own 11.10% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have recently issued reports on ANIP shares. StockNews.com lowered ANI Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, April 24th. Guggenheim restated a “buy” rating and issued a $86.00 price target on shares of ANI Pharmaceuticals in a research note on Monday. Jefferies Financial Group started coverage on ANI Pharmaceuticals in a research note on Friday, March 14th. They issued a “buy” rating and a $80.00 price target on the stock. JPMorgan Chase & Co. started coverage on ANI Pharmaceuticals in a research note on Wednesday, March 12th. They issued an “overweight” rating and a $85.00 price target on the stock. Finally, Truist Financial upped their price target on ANI Pharmaceuticals from $62.00 to $65.00 and gave the stock a “hold” rating in a research note on Monday, April 21st. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, ANI Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $80.13.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.